|
|
Latest oncology clinical development updates
Monday, February 02, 2026
|
|
|
|
|
OTW News Highlights this week
|
|
|
|
|
|
|
|
|
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said: “The rapid progress of our Phase II BTC study reflects the strong confidence investigators and patients have placed in the encouraging efficacy signals generated by Opamtistomig to date. Immune-cold tumors remain among the greatest challenges in oncology and represent one of the most important frontiers for next generation immunotherapy. Across …
|
|
|
|
|
|
|
|
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: “MSS/pMMR mCRC is widely recognized as an immunologically ‘cold’ tumor, and patients continue to face significant unmet medical needs with limited effective treatment options. Through the synergistic dual targeting of PD-L1 and 4-1BB, Opamtistomig has the potential to restore anti-tumor immune activity in cold tumors, a differentiated mechanism that has …
|
|
|
|
|
|
|
|
"While the results we are announcing today fell short of our expectations, they do not diminish our confidence in the broader potential of selinexor and benefit of XPO1 inhibition," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "We remain focused on maximizing our opportunity in myelofibrosis and continuing to build on our profitable multiple myeloma business. Looking ahead, …
|
|
|
|
|
|
|
|
Walter Klemp, Chairman and Chief Executive Officer of Moleculin, commented, “Nearly half of our evaluable subjects have now entered the trial having failed prior venetoclax therapy, a group for which published salvage remission rates are approximately 13% and median survival approximately 2.4 months. Within that subgroup, our blinded CRc is also approximately 37%, indistinguishable from the evaluable population as a …
|
|
|
|
|
|
|
|
AIM Chief Executive Officer Thomas Equels stated: “While the tremendous improvement in overall survival seen in our Named Patient Program is an important signal, it is one which requires Phase 2 and Phase 3 clinical trials to verify efficacy and support statistical validity. The execution of DURIPANC Phase 2 milestones ahead of schedule affirms our commitment to analyze biomarker stratifications …
|
|
|
|
|
|
|
|
"The early momentum we are seeing in OVATION 3 reflects the strength of our clinical data, the quality of our sites and the commitment of the investigators and patients participating in the trial," said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. "We've seen enrollment build quarter after quarter, including through the early summer months when trials typically …
|
|
|
|
|
|
|
|
“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,” said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. “As we march the ATLAS trial forward and prepare for our 5th IND filing, these proceeds are instrumental across the development and ultimately the supply …
|
|
|
|
|
|
|
|
FUJIFILM Corporation and Taiho Pharmaceutical announced that they have entered into a strategic partnership agreement for the development of manufacturing technologies for next-generation antibody-drug conjugates. Under this partnership, the two companies will work to optimize manufacturing processes for ADC candidates being developed by Taiho Pharmaceutical using the AraLinQ™ technology of Araris Biotech AG, a subsidiary of Taiho Pharmaceutical. By combining …
|
|
|
|
|
|
|
|
|
|
Author
Managing Editors
Social Media Managers
|
|
|
|
|
|
Disclaimer: The OTW team take care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is a part of RLS Consultants, which is a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.
|
|
|
|
|
|
